Illumina Non-GAAP EPS of $1.44 beats by $0.08, revenue of $1.13B misses by $20M (NASDAQ:ILMN)

Illumina reported Q3 Non-GAAP EPS of $1.44, exceeding estimates by $0.08, with revenue of $1.13B, missing by $20M. The company expects fiscal year 2026 revenue of $4.64B-$4.66B, excluding tariff refunds, according to a press release.

Original reporting
Published Oct 29, 2026, 8:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 8:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ILMN
Neutral
high confidence
Mentioned
$ILMN
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$ILMNNeutralMed
01

Why it matters

The earnings beat may provide short‑term support, but the revenue miss and modest guidance could cap upside.

02

Market read

Earnings release provides fresh data for traders; mixed signals suggest cautious positioning.

03

What to watch

Potential impact of upcoming regulatory changes on sequencing pricing not reflected in the guidance.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

Illumina's Q3 results were released via a press release on Oct 29, 2026.

Company-level read

Ticker impact

$ILMNNeutralHigh confidence
Context

Illumina reported Q3 Non‑GAAP EPS of $1.44, beating expectations by $0.08, while revenue of $1.13B missed by $20M and provided FY2026 revenue guidance of $4.64‑$4.66B.

Expected impact

mixed pressure as investors weigh the EPS beat against the revenue shortfall and modest guidance

Evidence & confidence

The surprise EPS beat may support the stock, but the revenue miss and guidance below consensus could limit upside.

Market effects

May influence other genomics and sequencing firms as investors compare earnings trends.

Primarily affects US biotech sector; limited broader market effect.

Limited to investors tracking Illumina and related biotech stocks.

Counterpoint

The revenue miss could signal slowing demand, suggesting a short‑term pullback despite the EPS beat.

Key entities

  • Illumina

    US‑listed genomics sequencing firm (NASDAQ:ILMN).

Related articles

$ILMNMed

Illumina selected to help bring precision medicine into everyday healthcare in Singapore

Illumina (ILMN) was selected for the SG-INSIGHT study, part of Singapore's National Precision Medicine program, to provide whole-genome sequencing for 450,000 residents. The study aims to integrate genomic data with healthcare to tailor treatments. Illumina will operate through its local facility, complying with Singapore's regulations. This follows their support in the previous phase of the program.

$ILMNHighAI 9/10

What Sent Illumina Stock Lower?

Illumina (ILMN) stock dropped 18.6% on October 30, 2026, despite beating earnings estimates and raising its full-year revenue outlook. The decline followed a mixed Q3 report where revenue missed estimates due to tariff refunds. Management cited strong sequencing consumables sales and NovaSeq X instrument placements. The broader market also fell, with AI-related stocks underperforming.

$ILMNHighAI 8/10

[Illumina Q3 2026 Earnings Call] Illumina Raises Full-Year Guidance to $4.64–$4.66 Billion as NovaSeq X Placements Top 80 and EPS Hits $1.44

Illumina reported Q3 2026 revenue of $1.17B, up 4.7% YoY, and EPS of $1.44. The company raised full-year guidance to $4.64–$4.66B, citing strong clinical demand and NovaSeq X placements. Operating margin was 25%, 100 bps ahead of guidance. Illumina expects 4.5% organic growth in Q4 and high-single-digit growth for 2027.